Fractyl Health Appoints Lara Smith Weber as New CFO to Drive Commercial-Stage Preparedness
GUTS has more than doubled off its 52-week low of $0.825.
Summary
Fractyl Health announced the appointment of Lara Smith Weber as its new Chief Financial Officer, effective January 12, 2026, replacing Lisa Davidson who resigned amicably after 10 years with the company.
Key Events · Executive and Board Changes · GUTS
-
New Chief Financial Officer Appointed
Lara Smith Weber has been appointed as the new Chief Financial Officer, effective January 12, 2026. She will oversee finance, accounting, and investor relations.
-
Outgoing CFO Resignation
Lisa Davidson resigned from her role as Chief Financial Officer, effective December 31, 2025, after 10 years with the company. Her resignation was not due to any disagreement.
-
New CFO Compensation Package
Ms. Smith Weber will receive a $150,000 signing bonus, an annual base salary of $492,100, a target annual bonus of 40% of her base salary, and an option to purchase 1,036,800 shares of common stock with a 4-year vesting period.
-
Outgoing CFO Severance and Consulting
Ms. Davidson will receive $630,000 in cash payments, up to 18 months of COBRA continuation, full vesting of outstanding time-based equity awards, an extended 12-month exercise period for vested options, and will provide consulting services for up to three months at $400 per hour.
Analysis · GUTS · Industrial Applications And Services
Fractyl Health's appointment of Lara Smith Weber as Chief Financial Officer is a very important development, signaling the company's strategic focus on transitioning to commercial-stage operations. Ms. Smith Weber's extensive experience in building financial organizations and guiding companies through operational scaling, as highlighted in the filing, directly aligns with Fractyl's stated 'pivotal moment.' The compensation package for the new CFO, particularly the grant of options for 1,036,800 shares, represents a significant equity incentive. The amicable departure of long-serving CFO Lisa Davidson, coupled with a substantial severance package including full vesting of time-based equity and a consulting agreement, ensures a smooth leadership transition. This change is positioned to strengthen the company's financial and operational discipline as it advances its clinical programs and prepares for commercialization.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GUTS was trading at $2.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $282.3M. The 52-week trading range was $0.83 to $3.03. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.